By Denny Jacob
Keros Therapeutics' market value dived after the biopharmaceutical company said it halted dosing in a trial of a treatment for pulmonary arterial hypertension following unexpected, adverse pericardial-effusion events.
Shares of the Lexington, Mass., company were down 71% at $19.69 in premarket trading, nearly wiping out a 73% gain from the start of the year.
The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg dosages of cibotercept, in combination with background therapy.
Dosing in a 1.5 mg/kg arm of the trial will continue, the company said, adding it expected to present topline data from all arms of the trial in the second quarter of next year.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 12, 2024 07:38 ET (12:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.